Clenasma (clenbuterol hydrochloride) Fat Loss Agents - Sympathomimetics profile

akn

Musclechemistry Member
<!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <w:punctuationKerning/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> <w:DontGrowAutofit/> <w:SplitPgBreakAndParaMark/> <w:DontVertAlignCellWithSp/> <w:DontBreakConstrainedForcedTables/> <w:DontVertAlignInTxbx/> <w:Word11KerningPairs/> <w:CachedColBalance/> <w:UseFELayout/> </w:Compatibility> <w:DoNotOptimizeForBrowser/> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="--"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument> </xml><![endif]--> [FONT=&quot]Description:[/FONT]
[FONT=&quot]Clenbuterol hydrochloride is an anti-asthma medication that[/FONT]
[FONT=&quot]belongs to a broad group of drugs knows as[/FONT]
[FONT=&quot]sympathomimetics. These drugs affect that sympathetic[/FONT]
[FONT=&quot]nervous system in a wide number of ways, largely mediated[/FONT]
[FONT=&quot]by the distribution of adrenoceptors. There are actually nine[/FONT]
[FONT=&quot]different types of these receptors in the body, which are[/FONT]
[FONT=&quot]classified as either alpha or beta and further subcategorized[/FONT]
[FONT=&quot]by type number. Depending on the specific affinities of these[/FONT]
[FONT=&quot]agents for the various receptors, they can potentially be used[/FONT]
[FONT=&quot]in the treatment of conditions such as asthma, hypertension,[/FONT]
[FONT=&quot]cardiovascular shock, arrhythmias, migraine headaches, and[/FONT]
[FONT=&quot]anaphylactic shock. The text [/FONT][FONT=&quot]Goodman and Gillman’s The[/FONT]
[FONT=&quot]Pharmacological Basis of Therapeutics 9th edition [/FONT][FONT=&quot]does a[/FONT]
[FONT=&quot]good job of describing the diverse nature in which these[/FONT]
[FONT=&quot]drugs affect the body:[/FONT]
Most of the actions of catecholamines and
sympathomimetic agents can be classified into seven broad
types: (1) peripheral excitatory action on certain types of
smooth muscles such as those in blood vessels supplying
the skin, kidney, and mucous membranes, and on the
cells, such as those of the salivary and sweat glands; (2) a
peripheral inhibitory action on certain other types of
smooth muscle, such as those in the wall of the gut, in the
bronchial tree, and in blood vessels supplying skeletal
muscle; (3) a cardiac excitatory action, responsible for an
increase in heart rate and force of contraction; (4)
metabolic actions, such as an increase in the rate of
glycogenolysis in liver and muscle and liberation of free
fatty acids from adipose tissue; (5) endocrine actions, such
as modulation of the secretion of insulin, rennin, and
pituitary hormones; (6) CNS actions, such as respiratory
stimulation and, with some of the drugs, an increase in
wakefulness and psychomotor activity and a reduction in
appetite; and (7) presynaptic actions that result in either
inhibition or facilitation of the release of the
neurotransmitters such as such as norepinephrine and
acetylcholine.
[FONT=&quot]Clenbuterol hydrochloride is specifically a selective beta-2[/FONT]
[FONT=&quot]sympathomimetic, primarily affecting only one of the three[/FONT]
[FONT=&quot]subsets of beta-receptors. Of particular interest is the fact[/FONT]
[FONT=&quot]that this drug has little beta-1 stimulating activity. Since beta-[/FONT]
[FONT=&quot]1 receptors are closely tied to the cardiac effects of these[/FONT]
[FONT=&quot]agents, this allows clenbuterol hydrochloride to reduce[/FONT]
[FONT=&quot]reversible airway obstruction (an effect of beta-2[/FONT]
[FONT=&quot]stimulation) with much less cardiovascular side effects[/FONT]
[FONT=&quot]compared to non-selective beta agonists. Clinical studies[/FONT]
[FONT=&quot]with this drug show it is extremely effective as a[/FONT]
[FONT=&quot]bronchodilator, with a low level of user complaints and high[/FONT]
[FONT=&quot]patient compliance . Clenbuterol hydrochloride also exhibits[/FONT]
[FONT=&quot]an extremely long half-life in the body, which is measured to[/FONT]
[FONT=&quot]be approximately 34 hours long. This makes steady blood[/FONT]
[FONT=&quot]levels easy to achieve, requiring only a single or twice daily[/FONT]
[FONT=&quot]dosing schedule at most. This of course makes it much easier[/FONT]
[FONT=&quot]for the patient to use, and may tie in to its high compliance[/FONT]
[FONT=&quot]rate.[/FONT]
[FONT=&quot]In animal studies clenbuterol hydrochloride is shown to[/FONT]
[FONT=&quot]exhibit anabolic activity, obviously an attractive trait to a[/FONT]
[FONT=&quot]bodybuilder or athlete. This compound is additionally a[/FONT]
[FONT=&quot]known thermogenic, with beta-2 agonists like clenbuterol[/FONT]
[FONT=&quot]hydrochloride shown to directly stimulate fat cells and[/FONT]
[FONT=&quot]accelerate the breakdown of triglycerides to form free fatty[/FONT]
[FONT=&quot]acids. Its efficacy in this area makes clenbuterol[/FONT]
[FONT=&quot]hydrochloride a very popular fat loss drug among the[/FONT]
[FONT=&quot]bodybuilding community. Those interested in this drug are[/FONT]
[FONT=&quot]often hoping it will produce a little of both benefits,[/FONT]
[FONT=&quot]promoting the loss of body fat while imparting increases in[/FONT]
[FONT=&quot]strength and muscle mass. But as was well pointed out by a[/FONT]
[FONT=&quot]review published in the August 1995 issue of Medicine and[/FONT]
[FONT=&quot]Science in Sports and Exercise[/FONT][FONT=&quot], the possible anabolic[/FONT]
[FONT=&quot]results in humans are very questionable, and based only on[/FONT]
[FONT=&quot]animal data using much larger doses than would be required[/FONT]
[FONT=&quot]for bronchodilation. With such reports there has been a lot of[/FONT]
[FONT=&quot]debate as to whether or not clenbuterol hydrochloride is[/FONT]
[FONT=&quot]really anabolic in humans at all. Some seem to swear by the[/FONT]
[FONT=&quot]fact that it builds muscle, and use clenbuterol hydrochloride[/FONT]
[FONT=&quot]regularly as an off-season or adjunct anabolic. To others, the[/FONT]
[FONT=&quot]MSSE report is confirmation that athletes have wasted[/FONT]
[FONT=&quot]valuable time and money on drugs that do not build muscle.[/FONT]
[FONT=&quot]The debate over clenbuterol hydrochloride’s potential[/FONT]
[FONT=&quot]anabolic activity continues today.[/FONT]
[FONT=&quot]History:[/FONT]
[FONT=&quot]Clenbuterol hydrochloride has been available as a[/FONT]
[FONT=&quot]bronchodilator for decades and is widely used in many parts[/FONT]
[FONT=&quot]of the world. Although it has a good safety record and[/FONT]
[FONT=&quot]approval in a wide number of other countries, this compound[/FONT]
[FONT=&quot]has never been made available for human use in the United[/FONT]
[FONT=&quot]States. The fact that there are a number of similar effective[/FONT]
[FONT=&quot]asthma medications already approved by the FDA and[/FONT]
[FONT=&quot]available may have something to do with this, as a[/FONT]
[FONT=&quot]prospective drug firm would likely not find it a profitable[/FONT]
[FONT=&quot]enough product to warrant undergoing the expense of the new[/FONT]
[FONT=&quot]drug approval process. Regardless of this fact, foreign[/FONT]
[FONT=&quot]clenbuterol hydrochloride preparations are popular among[/FONT]
[FONT=&quot]U.S. bodybuilders and athletes, and today are widely[/FONT]
[FONT=&quot]available on the black market. Note that in recent years,[/FONT]
[FONT=&quot]clenbuterol overdose/poisoning has been reported in a[/FONT]
[FONT=&quot]number of people, striking up a great deal of controversy[/FONT]
[FONT=&quot]about the safety of this drug and its off-label use for[/FONT]
[FONT=&quot]physique- and performance-enhancing purposes.[/FONT]
[FONT=&quot]How Supplied:[/FONT]
[FONT=&quot]Clenbuterol hydrochloride is most commonly supplied in[/FONT]
[FONT=&quot]oral tablets of 20 mcg each. It is also supplied in oral syrups,[/FONT]
[FONT=&quot]injectable solutions, and for inhalation use.[/FONT]
[FONT=&quot]Structural Characteristics:[/FONT]
[FONT=&quot]Clenbuterol hydrochloride is a long-acting selective‚ 2-[/FONT]
[FONT=&quot]adrenergic receptor agonist. It has the chemical designation[/FONT]
[FONT=&quot]1-(4-amino-3,5-dichloro-phenyl)-2-(tertbutylamino) ethanol.[/FONT]
[FONT=&quot]Side Effects:[/FONT]
[FONT=&quot]The possible side effects of clenbuterol hydrochloride[/FONT]
[FONT=&quot]include those of other CNS stimulants, and include such[/FONT]
[FONT=&quot]occurrences as shaky hands, insomnia, sweating, increased[/FONT]
[FONT=&quot]blood pressure, and nausea. These side effects will generally[/FONT]
[FONT=&quot]subside after a week or so of use, once the user becomes[/FONT]
[FONT=&quot]accustomed to the drug. Clenbuterol hydrochloride is a CNS[/FONT]
[FONT=&quot]stimulant with potential for fatal overdose. Signs of overdose[/FONT]
[FONT=&quot]may include rapid breathing, blood pressure irregularities,[/FONT]
[FONT=&quot]irregular heartbeat, unconsciousness, trembling, shaking,[/FONT]
[FONT=&quot]panic, extreme restlessness, and severe nausea, vomiting, or[/FONT]
[FONT=&quot]diarrhea.[/FONT]
[FONT=&quot]Administration:[/FONT]
[FONT=&quot]When used for the management of asthma, the most common[/FONT]
[FONT=&quot]clinical dose for adults is 20 mcg (1 tablet) twice per day.[/FONT]
[FONT=&quot]Some patients require up to 40 mcg (2 tablets) twice per day.[/FONT]
[FONT=&quot]When using the drug (off-label) for physique- or[/FONT]
[FONT=&quot]performance-enhancing purposes, bodybuilders and athletes[/FONT]
[FONT=&quot]generally tailor their dosage and cycling of this product[/FONT]
[FONT=&quot]based on personal sensitivity to its benefits and side effects.[/FONT]
[FONT=&quot]To accomplish this, one often begins a cycle by taking one or[/FONT]
[FONT=&quot]two tablets per day, and gradually increasing the dosage[/FONT]
[FONT=&quot]every third day by one half to 1 tablet until a desired dosage[/FONT]
[FONT=&quot]range is established. At peak therapy some users can tolerate[/FONT]
[FONT=&quot]as many as 6-8 tablets per day (120-160 mcg). Given the[/FONT]
[FONT=&quot]potency and potential for serious side effects, however, any[/FONT]
[FONT=&quot]dosage outside of the normal therapeutic range should be[/FONT]
[FONT=&quot]approached with an even greater level of caution.[/FONT]
[FONT=&quot]The drug will usually elevate the body temperature shortly[/FONT]
[FONT=&quot]after therapy is initiated. The rise in temperature is[/FONT]
[FONT=&quot]commonly .5 to 1 degree, sometimes a little more. This[/FONT]
[FONT=&quot]elevation is due to one’s body burning excess energy (largely[/FONT]
[FONT=&quot]from fat), and is usually not uncomfortable. The number of[/FONT]
[FONT=&quot]consecutive days clenbuterol hydrochloride is now used is[/FONT]
[FONT=&quot]usually dependent on the response of the individual. To be[/FONT]
[FONT=&quot]clear, the athletic benefits of this drug will only last for a[/FONT]
[FONT=&quot]limited time and then diminish, largely due to beta-receptor[/FONT]
[FONT=&quot]down regulation. By most accounts clenbuterol[/FONT]
[FONT=&quot]hydrochloride seems to work well for approximately 4 to 6[/FONT]
[FONT=&quot]weeks. During this period, users generally monitor their body[/FONT]
[FONT=&quot]temperature on a regular basis. We are given some level of[/FONT]
[FONT=&quot]assurance that clenbuterol hydrochloride is working by the[/FONT]
[FONT=&quot]temperature elevation. Once the temperature drops back to[/FONT]
[FONT=&quot]normal, receptor down regulation has probably diminished[/FONT]
[FONT=&quot]the efficacy of the drug. At this point increasing the dosage is[/FONT]
[FONT=&quot]usually not regarded as effective, and instead clenbuterol[/FONT]
[FONT=&quot]hydrochloride is discontinued for a period of no less than 4-6[/FONT]
[FONT=&quot]weeks.[/FONT]
[FONT=&quot]Many bodybuilding competitors enhance the fat burning[/FONT]
[FONT=&quot]effect of clenbuterol hydrochloride with the use of additional[/FONT]
[FONT=&quot]substances. Many have commented that when the drug is[/FONT]
[FONT=&quot]combined with thyroid hormones, specifically the powerful[/FONT]
[FONT=&quot]Cytomel®, the thermogenic effect can become extremely[/FONT]
[FONT=&quot]dramatic. Such a mix is often further used during a steroid[/FONT]
[FONT=&quot]cycle, helping the individual elicit a much more toned[/FONT]
[FONT=&quot]physique from the drugs. A clenbuterol/thyroid mix is also[/FONT]
[FONT=&quot]common when using growth hormone, which is believed to[/FONT]
[FONT=&quot]enhance the thermogenic and anabolic effect of HGH therapy.[/FONT]
[FONT=&quot]Lastly, ketotifen has also been a popular adjunct to[/FONT]
[FONT=&quot]clenbuterol hydrochloride, which is an antihistamine that[/FONT]
[FONT=&quot]upregulates beta-2 receptor density. It seems capable of not[/FONT]
[FONT=&quot]only increasing the potency of each dose of clenbuterol[/FONT]
[FONT=&quot]hydrochloride (allowing the user to take less clenbuterol),[/FONT]
[FONT=&quot]but also of perhaps even slowing receptor down regulation[/FONT]
[FONT=&quot](see the Ketotifen profile for a more comprehensive[/FONT]
[FONT=&quot]discussion).[/FONT]
[FONT=&quot]Availability:[/FONT]
[FONT=&quot]Clenbuterol hydrochloride is readily available on the[/FONT]
[FONT=&quot]international market. Although it is usually a very cheap drug[/FONT]
[FONT=&quot]in common source countries, allowing black market dealers[/FONT]
[FONT=&quot]ample opportunity to obtain legitimate drugs to divert for[/FONT]
[FONT=&quot]sale, clenbuterol hydrochloride has been the subject of lowlevel[/FONT]
[FONT=&quot]counterfeiting. A few things are important to note:[/FONT]
[FONT=&quot]Clenbuterol hydrochloride is not produced in the U.S., so[/FONT]
[FONT=&quot]avoid anything bearing a U.S. company name.[/FONT]
[FONT=&quot]Clenbuterol hydrochloride should only be trusted when found[/FONT]
[FONT=&quot]with a proper brand name from a foreign drug maker.[/FONT]
[FONT=&quot]Spiropent, Novegam, and Oxyflux from Mexico are the most[/FONT]
[FONT=&quot]common products in the U.S.[/FONT]
[FONT=&quot]From Europe, the brand names of Spiropent, Broncoterol,[/FONT]
[FONT=&quot]Clenasma, Monores, Contraspasmin, and Ventolase are[/FONT]
[FONT=&quot]popular.[/FONT]
[FONT=&quot]Bulgarian clenbuterol hydrochloride is also found commonly,[/FONT]
[FONT=&quot]but so are counterfeits. This is a slightly higher risk item[/FONT].
<!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0in; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;} </style> <![endif]-->
 
Back
Top